Lynx and GenoMar Enter Marine Genomics Collaboration

-Companies to Accelerate Breeding Freshwater Tilapia

For Saltwater Farming Environment-



Apr 11, 2001, 01:00 ET from Lynx Therapeutics, Inc. and GenoMar ASA

    HAYWARD, Calif., and OSLO, Norway, April 11 /PRNewswire/ --
 Lynx Therapeutics, Inc. (Nasdaq:   LYNX) and GenoMar ASA of Norway announced
 today they will use Lynx's Megasort(TM) technology to identify genes
 associated with saltwater tolerance in the tropical fin fish, Tilapia, one of
 the most widely farmed species in aquaculture.  Although Tilapia is currently
 farmed in freshwater, genes identified through this collaboration could be
 instrumental in accelerating the breeding of Tilapia suitable for saltwater
 farming environments around the world, thus increasing the availability
 globally to farm this valuable fish.
     "GenoMar is excited about the opportunity to employ Lynx's powerful
 technologies to detect differential gene expression patterns with greater
 speed and precision, thus, strengthening our breeding programs," stated Dr.
 Oystein Lie, Founder and Chief Executive Officer of GenoMar.  "This
 collaborative research agreement could provide great insight into the genetic
 mechanisms behind commercially important traits in Tilapia, a fish viewed in
 the aquaculture industry as the 'aquatic chicken.'  GenoMar, with its leading
 position as a life science-based aqua breeding enterprise, is looking forward
 to providing Lynx with an interesting market gateway to a new and fast growing
 industry."
     Under the terms of the agreement, GenoMar will provide Lynx with RNA
 samples from Tilapia raised in either freshwater or saltwater, which will then
 be compared using Lynx's Megasort(TM) technology.  Genes associated with
 growth in saltwater are expected to provide economically important tools in
 improving the performance of farmed fish through selective breeding.
     Lynx will receive payments from GenoMar for performing genomics discovery
 services. No other financial terms of the agreement were disclosed.
     "We are delighted that GenoMar, a global leader in marine genomics and
 genetics, has chosen Lynx's technologies to enhance its expertise in this area
 of growing need and importance," stated Dr. Norrie Russell, President and
 Chief Executive Officer of Lynx.  "We believe that the application of Lynx's
 technologies to aquaculture further displays the broad commercial breadth and
 reach of our products."
     Tilapia is believed to be the most important white fish in aquaculture,
 and farming of Tilapia is growing rapidly to meet demand for food protein.
 Additionally, fish farming is expected to provide a growing percentage of the
 worldwide fish supply over the next 20 years.  While Tilapia remains an
 important source of food protein to populations in developing nations, farming
 and consumption are rapidly increasing in the U.S., with sales of Tilapia
 exceeding that of trout every year since 1995.
 
     About Megasort(TM) Technology
     Megasort(TM) technology provides a method to identify and physically
 extract essentially all genes that differ in expression levels between two
 samples.  Megasort(TM) technology compares two DNA samples, each containing
 millions of molecules, and extracts those DNA molecules that are present in
 different proportions in the samples.  Because the comparison and sorting
 process requires no prior knowledge of the sequences of the genes in either
 sample, Megasort(TM) technology can be used with samples isolated from tissues
 or organisms that are not well characterized.
 
     About the Companies
     GenoMar applies genomics and bioinformatics to disclose structure and
 function of economically important genes in aquaculture species and their
 pathogens.  From its research in marine genomics and bioinformatics, several
 product categories are being developed and commercialized.  The information is
 used to improve breeding and to develop efficient disease control systems.
 GenoMar is using DNA typing assisted breeding to improve both its own Tilapia
 brood stock (in the Philippines) as well as serving several other large
 aquaculture companies with its expertise in their breeding efforts.  GenoMar
 was founded in 1996 by Professor Oystein Lie and co-founders from the
 Norwegian College of Veterinary Medicine.  For more information, please visit
 http://www.genomar.com.
 
     Lynx is a leader in the development and application of novel technologies
 for the discovery of gene expression patterns and genomic variations important
 to the pharmaceutical, biotechnology and agricultural industries.  These
 approaches are based on Megaclone(TM) technology, Lynx's unique and
 proprietary cloning procedure, which transforms a sample containing millions
 of DNA molecules into one made up of millions of micro-beads, each of which
 (referred to as a DNA analysis template) carries approximately 100,000 copies
 of one of the DNA molecules in the sample.  Lynx prepares nearly 100 million
 of such DNA analysis templates every week for subsequent analyses.
 Megaclone(TM) technology is the foundation for Lynx's analytical applications,
 including: Massively Parallel Signature Sequencing, or MPSS(TM), technology,
 which provides gene sequence information and high-resolution gene expression
 data including even the very rare transcripts; Megasort(TM) technology, which
 provides differentially expressed gene sets; and Megatype(TM) technology,
 which is expected to provide single nucleotide polymorphism, or SNP,
 disease- or trait-association information.  For more information, please visit
 http://www.lynxgen.com.
 
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the "safe
 harbor" provisions of the Private Securities Litigation Reform Act of 1995.
 These statements include those related to the identification of differentially
 expressed genes, as well as the potential success of collaboration
 arrangements.  Lynx cautions readers that forward-looking statements are
 subject to certain risks and uncertainties that could cause actual results to
 differ materially from those indicated in the forward-looking statements.
 These risks and uncertainties can include the failure to discover any product
 candidates as a result of the collaboration; the possible failure of any
 clinical trials or other tests for product candidates that arise from the
 collaboration; the inability to successfully market products; Lynx's inability
 to identify differentially expressed genes; the prospect of continued losses
 by Lynx; and other risks identified from time to time in Lynx's reports filed
 with the U.S. Securities and Exchange Commission.  Lynx directs readers to its
 reports filed with the U.S. Securities and Exchange Commission, including its
 Annual Report on Form 10-K for the year ended December 31, 2000.  The
 information in this press release is current as of its release date.  Lynx
 takes no responsibility to update the information.
 
 

SOURCE Lynx Therapeutics, Inc. and GenoMar ASA
    HAYWARD, Calif., and OSLO, Norway, April 11 /PRNewswire/ --
 Lynx Therapeutics, Inc. (Nasdaq:   LYNX) and GenoMar ASA of Norway announced
 today they will use Lynx's Megasort(TM) technology to identify genes
 associated with saltwater tolerance in the tropical fin fish, Tilapia, one of
 the most widely farmed species in aquaculture.  Although Tilapia is currently
 farmed in freshwater, genes identified through this collaboration could be
 instrumental in accelerating the breeding of Tilapia suitable for saltwater
 farming environments around the world, thus increasing the availability
 globally to farm this valuable fish.
     "GenoMar is excited about the opportunity to employ Lynx's powerful
 technologies to detect differential gene expression patterns with greater
 speed and precision, thus, strengthening our breeding programs," stated Dr.
 Oystein Lie, Founder and Chief Executive Officer of GenoMar.  "This
 collaborative research agreement could provide great insight into the genetic
 mechanisms behind commercially important traits in Tilapia, a fish viewed in
 the aquaculture industry as the 'aquatic chicken.'  GenoMar, with its leading
 position as a life science-based aqua breeding enterprise, is looking forward
 to providing Lynx with an interesting market gateway to a new and fast growing
 industry."
     Under the terms of the agreement, GenoMar will provide Lynx with RNA
 samples from Tilapia raised in either freshwater or saltwater, which will then
 be compared using Lynx's Megasort(TM) technology.  Genes associated with
 growth in saltwater are expected to provide economically important tools in
 improving the performance of farmed fish through selective breeding.
     Lynx will receive payments from GenoMar for performing genomics discovery
 services. No other financial terms of the agreement were disclosed.
     "We are delighted that GenoMar, a global leader in marine genomics and
 genetics, has chosen Lynx's technologies to enhance its expertise in this area
 of growing need and importance," stated Dr. Norrie Russell, President and
 Chief Executive Officer of Lynx.  "We believe that the application of Lynx's
 technologies to aquaculture further displays the broad commercial breadth and
 reach of our products."
     Tilapia is believed to be the most important white fish in aquaculture,
 and farming of Tilapia is growing rapidly to meet demand for food protein.
 Additionally, fish farming is expected to provide a growing percentage of the
 worldwide fish supply over the next 20 years.  While Tilapia remains an
 important source of food protein to populations in developing nations, farming
 and consumption are rapidly increasing in the U.S., with sales of Tilapia
 exceeding that of trout every year since 1995.
 
     About Megasort(TM) Technology
     Megasort(TM) technology provides a method to identify and physically
 extract essentially all genes that differ in expression levels between two
 samples.  Megasort(TM) technology compares two DNA samples, each containing
 millions of molecules, and extracts those DNA molecules that are present in
 different proportions in the samples.  Because the comparison and sorting
 process requires no prior knowledge of the sequences of the genes in either
 sample, Megasort(TM) technology can be used with samples isolated from tissues
 or organisms that are not well characterized.
 
     About the Companies
     GenoMar applies genomics and bioinformatics to disclose structure and
 function of economically important genes in aquaculture species and their
 pathogens.  From its research in marine genomics and bioinformatics, several
 product categories are being developed and commercialized.  The information is
 used to improve breeding and to develop efficient disease control systems.
 GenoMar is using DNA typing assisted breeding to improve both its own Tilapia
 brood stock (in the Philippines) as well as serving several other large
 aquaculture companies with its expertise in their breeding efforts.  GenoMar
 was founded in 1996 by Professor Oystein Lie and co-founders from the
 Norwegian College of Veterinary Medicine.  For more information, please visit
 http://www.genomar.com.
 
     Lynx is a leader in the development and application of novel technologies
 for the discovery of gene expression patterns and genomic variations important
 to the pharmaceutical, biotechnology and agricultural industries.  These
 approaches are based on Megaclone(TM) technology, Lynx's unique and
 proprietary cloning procedure, which transforms a sample containing millions
 of DNA molecules into one made up of millions of micro-beads, each of which
 (referred to as a DNA analysis template) carries approximately 100,000 copies
 of one of the DNA molecules in the sample.  Lynx prepares nearly 100 million
 of such DNA analysis templates every week for subsequent analyses.
 Megaclone(TM) technology is the foundation for Lynx's analytical applications,
 including: Massively Parallel Signature Sequencing, or MPSS(TM), technology,
 which provides gene sequence information and high-resolution gene expression
 data including even the very rare transcripts; Megasort(TM) technology, which
 provides differentially expressed gene sets; and Megatype(TM) technology,
 which is expected to provide single nucleotide polymorphism, or SNP,
 disease- or trait-association information.  For more information, please visit
 http://www.lynxgen.com.
 
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the "safe
 harbor" provisions of the Private Securities Litigation Reform Act of 1995.
 These statements include those related to the identification of differentially
 expressed genes, as well as the potential success of collaboration
 arrangements.  Lynx cautions readers that forward-looking statements are
 subject to certain risks and uncertainties that could cause actual results to
 differ materially from those indicated in the forward-looking statements.
 These risks and uncertainties can include the failure to discover any product
 candidates as a result of the collaboration; the possible failure of any
 clinical trials or other tests for product candidates that arise from the
 collaboration; the inability to successfully market products; Lynx's inability
 to identify differentially expressed genes; the prospect of continued losses
 by Lynx; and other risks identified from time to time in Lynx's reports filed
 with the U.S. Securities and Exchange Commission.  Lynx directs readers to its
 reports filed with the U.S. Securities and Exchange Commission, including its
 Annual Report on Form 10-K for the year ended December 31, 2000.  The
 information in this press release is current as of its release date.  Lynx
 takes no responsibility to update the information.
 
 SOURCE  Lynx Therapeutics, Inc. and GenoMar ASA